BioInvent at PEGS Europe 2026

Nov 16–19, 2026 Lisbon, Portugal ~1.5k attendees Website

BioInvent brings 3 presentations to PEGS Europe 2026 in Lisbon. Its program centres on cancer immunotherapy and where clinical outcomes in the field now stand. It compares ways of using TNF receptors against tumours, either by depleting regulatory T cells and reprogramming myeloid cells or by boosting T cell co-stimulation.

OrganizationPEGS Europe 2026 Attendance
BioInvent
Lund, Sweden
bioinvent.com
Biotech
Clinical-stage company developing immune-modulating antibodies, including anti-TNFR2 and anti-FcγRIIB antibodies, for cancer.
Chair
Thu Nov 19
8:25am–8:30am
Chairperson's Remarks
Next-Generation Immunotherapies
Talk
Thu Nov 19
2:35pm–3:05pm
Panel
Thu Nov 19
3:35pm–4:15pm
Clinical Outcomes in Immunotherapy—Where Are We Now?
Next-Generation Immunotherapies · with Accession Therapeutics, Immatics, Dr. Rosell Oncology Institute, Dexeus University Hospital +2 more

Explore the full PEGS Europe 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Lisbon. Leave your work email and we’ll be in touch.

Privacy

Download the full PEGS Europe 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from BioInvent

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by PEGS Europe or its organizers. Submit a correction